

Hemophilia A Market Size in the 7MM was ~USD 11,200 Million in 2023, estimated DelveInsight

Hemophilia A Market

DELHI, DELHI, INDIA, July 1, 2024 /EINPresswire.com/ -- DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Hemophilia A Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Hemophilia A Market Forecast. Click here to stay ahead in healthcare innovation @ [Hemophilia A Market Size](#)

Key Takeaways from the Hemophilia A Market Report

- June 2024:- Novo Nordisk A/S- This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A.
- June 2024:- Bayer- A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A.
- June 2024:- Pfizer- The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called marstacimab) for the potential treatment of hemophilia in pediatric patients. This study will enroll pediatric participants from ages 1 to 17 years in a sequential manner. The study will open enrollment to adolescent participants aged 12 to 17 years first. Then children aged 6 to 11 years will be permitted to enroll. Lastly, children aged 1 to 5 years will be permitted to enroll.
- June 2024:- Hoffmann- La Roche- A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors.
- According to DelveInsight's analysis, severe cases of Hemophilia A are more prominent in comparison to mild and moderate cases.
- As per Centers for Disease Control (CDC) (2020), the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 US males for hemophilia A.
- According to Ei et al. (2018), a survey was conducted in 2018 in Japan which reported 5301

cases of Hemophilia A from total 8751 cases of involved.

- The leading Hemophilia A Companies such as BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.
- Promising Hemophilia A Therapies such as dirloctocogene samoparvovec (RG6357 or SPK-8011), fitusiran (ALN-AT3, SAR-439774), marstacimab (PF-06741086), and others

Delve deep into the Hemophilia A Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Hemophilia A Market Forecast. Click here to shape the future @ [Hemophilia A Prevalence](#)

Hemophilia A Overview

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. Without enough factor VIII, the blood cannot clot properly to control bleeding. Although it is passed down from parents to children, about 1/3 of cases found have no previous family history.

Hemophilia A Epidemiology Insights

- Total Hemophilia A Diagnosed Prevalent Pool
- Hemophilia A Inhibitor-specific Prevalent Pool
- Hemophilia A Treated Prevalent Pool
- Hemophilia A Severity-specific Prevalent Pool

Navigate the complexities of the Hemophilia A Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Hemophilia A Market Forecast. Click here to get more insights @ [Hemophilia A Treatment Market](#)

Hemophilia A Market Insights

Hemophilia A is a life-long condition. Currently, there is no cure, but researchers are actively engaged in finding the cure through gene therapy. One hope is that by inserting a healthy version of the defective blood factor gene, a person with hemophilia will be able to produce reasonable amounts of a factor on their own. Generally, Hemophilia A patients are provided with "On Demand" and "Prophylaxis" treatment. But Prophylaxis treatment option has gained importance in comparison to the on-demand treatment options.

Hemophilia A Therapeutics Market

The current therapeutic landscape of Hemophilia A in the United States is driven by several approved therapies. The market for Hemophilia A is estimated to grow for the period 2019-2032. The major reason behind market upsurge is the launch of the most anticipated gene therapies, which are considered as a threat to the current market.

Unlock insights into the Hemophilia A Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Hemophilia A Market Forecast. Click

here @ Hemophilia A Market Drivers and Barriers- https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Hemophilia A Marketed Drugs

- ROCTAVIAN (valoctocogene roxaparvec)
- OBIZUR (susoctocog alfa): Takeda

Hemophilia A Emerging Drugs

- Fitusiran: Sanofi
- Marstacimab: Pfizer

Scope of the Hemophilia A Market Report

- Coverage- 7MM
- Hemophilia A Companies- BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.
- Hemophilia A Therapies- dirloctocogene samoparvec (RG6357 or SPK-8011), fitusiran (ALN-AT3, SAR-439774), marstacimab (PF-06741086), and others.
- Hemophilia A Market Dynamics: Hemophilia A Market drivers and Hemophilia A Market Barriers
- Hemophilia A Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Hemophilia A Unmet Needs, KOL's views, Analyst's views, Hemophilia A Market Access and Reimbursement

Gain a strategic edge in the Hemophilia A Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Hemophilia A Market Forecast. Click here to lead in advancements @ Hemophilia A Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Report Introduction
3. Hemophilia A Market Overview at a Glance
4. Executive Summary of Hemophilia A
5. Key Events
6. SWOT Analysis
7. Epidemiology and Market Methodology
8. Hemophilia A: Disease Background and Overview
9. Treatment Algorithm, Current Treatment, and Medical Practices
10. Epidemiology and Patient Population

11. Patient Journey of Hemophilia A
12. Key Endpoints in Hemophilia A Clinical Trials
13. Marketed Drugs
14. Emerging Drugs
15. Hemophilia A: Seven Major Market Analysis
16. Market Access and Reimbursement
17. Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/724211097>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.